Comparative Pharmacology
Head-to-head clinical analysis: QOLIANA versus TAPENTADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QOLIANA versus TAPENTADOL.
QOLIANA vs TAPENTADOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
None Documented
None Documented
Clinical Note
moderateTapentadol + Torasemide
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide."
Clinical Note
moderateTapentadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid."
Clinical Note
moderateTapentadol + Furosemide
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide."
Clinical Note
moderateTapentadol + Bumetanide
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Category C
Category A/B
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide."